Merck & Co., Inc. (MRK)

The company now

Merck, known as MSD outside the United States and Canada, reports its third-quarter 2026 results on 29 October, with a call for analysts at 9:00 in the morning, Eastern time 9. Its last reported quarter, the second, brought sales of $16.6 billion, up 5 percent, with Keytruda, its cancer immunotherapy, at $8.4 billion 1. It still reported a loss of $0.54 a share, because buying Terns Pharmaceuticals, a cancer drug developer, brought a one-time charge of $5.7 billion 1.

This month brought two large trial results at the ESMO cancer congress 78. Merck and Moderna reported that their personalized mRNA vaccine, intismeran, added to Keytruda cut the risk of melanoma returning or death by 42 percent against Keytruda alone 7. Merck's own sac-TMT, a targeted chemotherapy, cut the risk of death by 32 percent in advanced endometrial cancer, and the FDA set a decision date of 15 June 2027 8.

The open question is how much of Keytruda these launches can replace: it made 49 percent of 2025 sales, and the company expects biosimilar copies from December 2028 3. In August it raised its 2026 sales outlook to between $66.3 billion and $67.3 billion 1.

As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.

Newer filings are on file since this was written; an update is queued.